Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 23;192(1):55-62.
doi: 10.1093/bjd/ljae336.

Uncovering the molecular mechanisms of amelanotic/hypopigmented primary cutaneous melanoma

Affiliations

Uncovering the molecular mechanisms of amelanotic/hypopigmented primary cutaneous melanoma

Richard A Sturm et al. Br J Dermatol. .

Abstract

Background: Approximately 2-20% of cutaneous melanomas (CMs) are diagnosed as amelanotic/hypopigmented melanoma (AHM) and represent a challenge for early diagnosis.

Objectives: To investigate loss-of-function mutations in key pigmentation genes in matched germline and AHM, as well as pigmented melanoma (PM), tumour DNA samples.

Methods: Analysis of clinical and histopathological characteristics - together with whole-exome sequencing data of 34 fresh frozen primary CMs, graded according to the amount of pigmentation present - was performed. Together with germline and somatic variant analysis, 30 samples had previously been analysed for copy number aberration (CNA) changes. This study focused on germline and somatic variants in the coding region of 16 genes known to be associated with albinism/hypopigmentation or variation in human pigmentation in all samples. Chromosomal regions encompassing these 16 genes were examined for DNA copy loss or gain.

Results: The finding that red hair-related MC1R and TYR R402Q loss-of-activity gene variant alleles and genotypes are associated with AHM was confirmed. Germline AHM-related gene variants were enriched in 70% (n = 7/10) of patients with AHM vs. 8% (n = 2/24) of those with PM. This surprisingly high frequency of rare germline variants in people with AHM constitutes the 'first hit' and confirms that those with AHM are more likely to be albinism allele carriers than individuals with PM. Next, in CNA analysis of each tumour sample, 50% (n = 4/8) of AHM samples with a pigmentation gene variant had loss of heterozygosity (LOH) in the region containing the corresponding gene and 25% (n = 2/8) had LOH in chromosomal regions of two AHM-related genes.

Conclusions: This study proposes that the likely molecular mechanism for the development of amelanogenesis in AHM is carriage of an albinism/hypopigmentation allele followed by LOH of the corresponding gene in the tumour.

Plain language summary

Melanoma is a form of skin cancer. Up to 20% of melanomas are flesh-coloured tumours. Other melanomas can be coloured or ‘pigmented’. These differences present a challenge when trying to diagnose melanoma early. A type of flesh-coloured melanoma called ‘amelanotic/hypomelanotic’ melanoma (or ‘AHM’ for short) often develops with sun damage and in older people. The loss of colour, or ‘pigment’, in AHM is caused by a decrease in the amount of a substance called melanin produced in the tumour cells. We looked at possible genetic differences between AHM and pigmented melanoma. We examined changes in key genes associated with decreases in skin colouring or gene mutations that cause albinism (where no melanin is produced). We found variants in genes that cause albinism or reduced pigmentation in 7 of 10 people with AHM. Only 2 of 24 people with pigmented melanoma had these genetic variants. Overall, the high frequency of gene variants in people with AHM, together with a loss of gene function in the tumour, supports the idea that some people could be predisposed to getting AHM. This provides an explanation for the loss of melanin in AHM tumours.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest H.P.S. is a shareholder of MoleMap NZ Limited and e-derm-consult GmbH, and undertakes regular teledermatological reporting for both companies. H.P.S. is a Medical Consultant for Canfield Scientific Inc. and MoleMap Australia Pty Ltd, and a Medical Advisor for First Derm. V.J.M. has received speaker fees from Novartis, Bristol Myers Squibb, Merck and Janssen, and has participated in Advisory Boards for MSD and L’Oréal. R.A.S. has received fees for professional services from SkylineDx BV, IO Biotech ApS, MetaOptima Technology Inc., F. Hoffmann-La Roche Ltd, Evaxion, Provectus Biopharmaceuticals Australia, Qbiotics, Novartis, Merck Sharp & Dohme, NeraCare, AMGEN Inc., Bristol Myers Squibb, Myriad Genetics and GlaxoSmithKline. The other authors declare no conflicts of interest.

Comment in

MeSH terms

Substances